Shenzhen Salubris Pharmaceuticals (002294.SZ): Innovative Small-Molecule Drug SAL0139 Approved for Clinical Trials in Hyperlipidemia Treatment

Stock News11-21

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) announced that it recently received the Clinical Trial Approval Notice issued by the National Medical Products Administration. The approval grants permission for the company to conduct clinical trials of its self-developed innovative small-molecule drug SAL0139 tablets (project code: SAL0139) for the treatment of hyperlipidemia.

Hyperlipidemia is a metabolic disorder characterized by its insidious nature and widespread harm. If left uncontrolled over time, it can lead to multi-system complications. Elevated low-density lipoprotein cholesterol (LDL-C) is a key risk factor contributing to cardiovascular and cerebrovascular diseases.

Preclinical studies indicate that SAL0139 has the potential to reduce LDL-C levels. If successfully developed and approved for market launch, the drug could provide a new treatment option for more patients, improve medication adherence, address unmet clinical needs, and further enrich the company's innovative product pipeline in the chronic disease sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119603610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 16:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119603610","market":"sg","top_or_hot":-1,"title":"Shenzhen Salubris Pharmaceuticals (002294.SZ): Innovative Small-Molecule Drug SAL0139 Approved for Clinical Trials in Hyperlipidemia Treatment","media":"Stock News","content":"<p>Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) announced that it recently received the Clinical Trial Approval Notice issued by the National Medical Products Administration. The approval grants permission for the company to conduct clinical trials of its self-developed innovative small-molecule drug SAL0139 tablets (project code: SAL0139) for the treatment of hyperlipidemia.</p>\n<p>Hyperlipidemia is a metabolic disorder characterized by its insidious nature and widespread harm. If left uncontrolled over time, it can lead to multi-system complications. Elevated low-density lipoprotein cholesterol (LDL-C) is a key risk factor contributing to cardiovascular and cerebrovascular diseases.</p>\n<p>Preclinical studies indicate that SAL0139 has the potential to reduce LDL-C levels. If successfully developed and approved for market launch, the drug could provide a new treatment option for more patients, improve medication adherence, address unmet clinical needs, and further enrich the company's innovative product pipeline in the chronic disease sector.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Salubris Pharmaceuticals (002294.SZ): Innovative Small-Molecule Drug SAL0139 Approved for Clinical Trials in Hyperlipidemia Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Salubris Pharmaceuticals (002294.SZ): Innovative Small-Molecule Drug SAL0139 Approved for Clinical Trials in Hyperlipidemia Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-21 16:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) announced that it recently received the Clinical Trial Approval Notice issued by the National Medical Products Administration. The approval grants permission for the company to conduct clinical trials of its self-developed innovative small-molecule drug SAL0139 tablets (project code: SAL0139) for the treatment of hyperlipidemia.</p>\n<p>Hyperlipidemia is a metabolic disorder characterized by its insidious nature and widespread harm. If left uncontrolled over time, it can lead to multi-system complications. Elevated low-density lipoprotein cholesterol (LDL-C) is a key risk factor contributing to cardiovascular and cerebrovascular diseases.</p>\n<p>Preclinical studies indicate that SAL0139 has the potential to reduce LDL-C levels. If successfully developed and approved for market launch, the drug could provide a new treatment option for more patients, improve medication adherence, address unmet clinical needs, and further enrich the company's innovative product pipeline in the chronic disease sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1119603610","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119603610","pubTimestamp":1763712517,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) announced that it recently received the Clinical Trial Approval Notice issued by the National Medical Products Administration. The approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0188":"融资融券","BK0196":"行业龙头","002294":"信立泰","BK0187":"一线龙头","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念"},"translate_title":"深圳赛百利药业（002294.SZ）：创新小分子药SAL0139获批高脂血症治疗临床","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002294":1},"content_text":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) announced that it recently received the Clinical Trial Approval Notice issued by the National Medical Products Administration. The approval grants permission for the company to conduct clinical trials of its self-developed innovative small-molecule drug SAL0139 tablets (project code: SAL0139) for the treatment of hyperlipidemia.\nHyperlipidemia is a metabolic disorder characterized by its insidious nature and widespread harm. If left uncontrolled over time, it can lead to multi-system complications. Elevated low-density lipoprotein cholesterol (LDL-C) is a key risk factor contributing to cardiovascular and cerebrovascular diseases.\nPreclinical studies indicate that SAL0139 has the potential to reduce LDL-C levels. If successfully developed and approved for market launch, the drug could provide a new treatment option for more patients, improve medication adherence, address unmet clinical needs, and further enrich the company's innovative product pipeline in the chronic disease sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119603610","isCrawlerRequest":true}